Randomized Phase II Trial of Anastrozole plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast Cancer
Phase 2
- Conditions
- Estrogen receptor (ER)-positive, HER2-negative postmenopausal primary breast cancer
- Registration Number
- JPRN-UMIN000006434
- Lead Sponsor
- Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 120
Inclusion Criteria
Not provided
Exclusion Criteria
1.Inoperable, multiple, bilateral (synchronous or asynchronous) or inflammatory breast cancer 2.Personal history of invasive carcinoma 3.Patients receive systemic therapy of corticosteroid 4.Patients receive estrogen preparation or raloxifene 5.Patients with other concurrent severe and/or uncontrolled medical disease 6.Patients whom doctors judged inadequate to the enrollment of this study by other reasons.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method